[Special Stock] JW Jungwoo Pharmaceutical Soars on FDA Approval for 'Actemra' COVID-19 Phase 3 Clinical Trial Application

[Asia Economy Reporter Minji Lee] JW Pharmaceutical's rheumatoid arthritis treatment 'Yactemra (active ingredient tocilizumab)' surged following news that it received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase 3 clinical trial for severe COVID-19. JW Pharmaceutical exclusively sells Actemra in South Korea.

At 11:37 AM on the 24th, JW Pharmaceutical was trading on the KOSPI market at 22,850 KRW, up 16.28% from the previous session. Additionally, JW Pharmaceutical Preferred Shares (24.64%) and JW Pharmaceutical 2nd Preferred Shares B (14.00%) also maintained upward trends.

On the previous day, the global pharmaceutical company Roche Group announced that the U.S. Food and Drug Administration (FDA) had authorized the initiation of a global Phase 3 clinical trial to confirm the efficacy of Actemra, a rheumatoid arthritis treatment, for COVID-19. This Phase 3 trial is expected to evaluate the safety and efficacy in adult patients with severe COVID-19 who are at risk of cytokine storm.

This content was produced with the assistance of AI translation services.